ReviewIndian heart journal2013
The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.
Review in Indian heart journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Review
- Article
- A Review of Emerging Biomarkers Connecting Diabetes and Ischemic Stroke: Implications for Early Detection and Risk Stratification.Journal of diabetes research · 2026Review
- Article
- Development and validation of a nomogram prediction model for coronary heart disease in diabetic patients: a study based on the 2011-2020 NHANES database.BMC cardiovascular disorders · 2025Article
- Type 2 diabetes and susceptibility to COVID-19: a machine learning analysis.BMC endocrine disorders · 2024Article
- Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Glycoprotein Profile Measured by aLife (Basel, Switzerland) · 2021Article
- Identification of key candidate genes and molecular pathways in white fat browning: an anti-obesity drug discovery based on computational biology.Human genomics · 2019Article
- Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence.Diabetes, metabolic syndrome and obesity : targets and therapy · 2015Review
- From 'Make in India' to 'Made in India': the saroglitazar story.Indian heart journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a pandemic disease and an important cardiovascular (CV) risk factor. The atherogenic dyslipidemia in diabetes (ADD) is characterized by high serum triglycerides, high small dense LDL levels, low HDL levels and postprandial lipemia. Insulin resistance is a primary cause for ADD. Though statins are highly effective for CVD prevention in DM but a significant residual CV risk remains even after optimal statin therapy. Fibrates, niacin and omega-3 fatty acids are used in addition to statin for treatment of ADD (specifically hypertriglyceridemia). All these drugs have some limitations and they are far from being ideal companions of statins. Many newer drugs are in pipeline for management of ADD. Dual PPAR α/γ agonists are in most advanced stage of clinical development and they have a rational approach as they control blood glucose levels (by reducing insulin resistance, a primary factor for ADD) in addition to modulating ADD. Availability of dual PPAR α/γ agnosits and other drugs for ADD management may improve CV outcomes and decrease morbidity and mortality in diabetic patients in future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.